A

# Insights into type 2 diabetes from rare coding variants 

Jason Flannick

flannick@broadinstitute.org
flannicklab.org





## Rare coding variants

## Back in 2008...



## The case of the missing heritability

When scientists opened up the human genome, they expected to find the genetic components of common traits and diseases. But they were nowhere to be seen. Brendan Maher shines a light on six places where the missing loot could be stashed away.

## Table 1 | Estimates of heritability and number of loci for several complex traits

| Disease | Number of loci | Fropi | Heritability measure |
| :---: | :---: | :---: | :---: |
| Age-related macular degeneration ${ }^{72}$ | 5 | 50\% | Sibling recurrence risk |
| Crohn's disease ${ }^{21}$ | 32 | 20\% | Genetic risk (liability) |
| Systemic lupus erythematosus ${ }^{73}$ | 6 | 15\% | Sibling recurrence risk |
| Type 2 diabetes ${ }^{74}$ | 18 | 6\% | Sibling recurrence risk |
| HDL cholesterol ${ }^{75}$ | 7 | 5.2\% | Residual* phenotypic variance |
| Height ${ }^{15}$ | 40 | 5\% | Phenotypic variance |
| Early onset myocardial infarction ${ }^{76}$ | 9 | 2.8\% | Phenotypic variance |
| Fasting glucose ${ }^{77}$ | 4 | 1.5\% | Phenotypic variance |

[^0]
## Classes of genetic variation




The case of the missing heritability When scientists opened up the human genome, they expected to find the genetic components of common traits and diseases. But they were nowhere to be seen. Brendan Maher shines a light on
six places where the missing loot could be stashed away. six places where the missing loot could be stashed away.


Are Rare Variants Responsible for Susceptibility to Complex Diseases?
Jonathan K. Pritchard
Department of Statistics, University of Oxford, Oxford
Common Genetic Variation and Human Traits David B. Goldstein, Ph.D.

## Genetic Heterogeneity in Human Disease

```
Jon McClellan,1,* and Mary-Claire King.,*
Department of Psychiatry
Departments of Medicine and Genome Sciences
University of Washington, Seattle, WA 98195-7720, USA
Correspondence: driack@uw.edu (J.M.), mcking@uw.edu (M.-C.K.)
Eorrespondence: driack@uw.edu (J.M.), mckingஞuw.edu (M.-C.K.)
DO1 10.1016/,.cell.2010.03.032
```


## Clan Genomics and the Complex Architecture of Human Disease

James R. Lupski, ${ }^{1,2,3, *}$ John W. Belmont, ${ }^{1,2}$ Eric Boerwinkle, ${ }^{4,5}$ and Richard A. Gibbs ${ }^{15,5 *}$

open a access freely avalable online $\quad$ PLOS BioLogr

Rare Variants Create Synthetic Genome-Wide Associations
Samuel P. Dickson ${ }^{1,2}$, Kai Wang $^{3}$, lan Krantz ${ }^{3,4,5}$, Hakon Hakonarson ${ }^{3,4,5}$, David B. Goldstein ${ }^{1 *}$

(O) APPLICATIONS OF NEXT-GENERATION SEQUENCING

## Uncovering the roles of rare

 variants in common disease through whole-genome sequencing
## GWAS: individual common variant associations


cases ( $\mathrm{n}=1,000$ ) people with heart disease

controls ( $n=1,000$ )
people without heart disease


## Rare variants: aggregate gene-level associations



## Early successes from targeted sequencing



## Early successes from targeted sequencing

12 loss-of-function SLC30A8 mutations in 149,134 individuals Aggregate odds ratio: 0.34

$$
p=1.7 \times 10^{-6}
$$

a Variants

b Frequencies


Biological insights

VS.

Genetic architecture


## Are rare variants responsible for a significant fraction of disease heritability?



Coding variation


Noncoding variation


Follow-up


## Main finding:



Are Rare Variants Responsible for Susceptibility to Complex Diseases?

Common Genetic Variation and Human Traits

Genetic Heterogeneity in Human Disease
Clan Genomics and the Complex
Architecture of Human Disease

## The case of the missing heritability

 When scientists opened up the human genome, they expected to find the genetic components of common traits and diseases. But they were nowhere to be seen. Brendan Maher shines a light on six places where the missing loot could be stashed away

Rare Variants Create Synthetic Genome-Wide
Associations

Common and rare variants in multifactorial Uncovering the roles of rare susceptibility to common diseases variants in common disease through whole-genome sequencing

## Since

## MIMR3

225
$\square$ African American
$\square$ East Asian
$\square$ European
$\square$ Hispanic or Native American
$\square$ South Asian
Initial sample size

C2CD4B-C2CD4A
ZFAND6
ZBED3
ZBED
ZBE
Linkage or candidate ge
GWAS or Metabochip GWAS or Met
Exome array Genome or exome sequencing Sample size (1,000s)


## Problem: what are the genes?

- Usually only one (or a few) variants are causal

b




## Meanwhile, rare variants...

- When significant: direct links from disease to genes
- When variants inactivate protein: directional link with disease risk



## More recent (45,000 sample) exome sequencing

- Three exome-wide significant gene-level associations

Gene-level associations


## Explaining minimal heritability

LVE of top cGWAS and exomes associations


## But: many signals beyond



## But: many signals beyond



## Further support for this model

## Beyond type 2 diabetes

- Study design:
- Exome sequencing of 85,474 non-diabetic individuals
- UKBB exomes ( $\mathrm{n}=40,151 ; 100 \%$ European)
- AMP-T2D exomes ( $n=45,323$; 15.8\% African American; 25.6\% East Asian; 18.7\% European; 18.0\% Hispanic; and 22.2\% South Asian)
- 24 quantitative traits
- Single variant analysis (mostly for common variants)
- Gene-level analysis (for rare variants)




## HbA1C is commonly used in T2D diagnosis



HbA1C Gene-Level Associations


## Common variants and HbA1C

~150,000
individuals
60 common variant associations


## Common variants and HbA1c

- Associations can be grouped into two classes

Associated with red blood cell traits

Associated with other glycemic traits

Table 1. (Continued)

| SNP | Markername | Chr. | Position (bp) | Effect Allele | Other Allele | Gene | Status | Signals | Classification | European ancestry METAL $p$-value | Trans-ethnic MANTRA $\log 10 B F$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 45 | rs10774625 | 12 | 110394602 | G | A | ATXN2 | Novel | Single | Erythrocytic | $1.45 \times 10^{-8}$ | 6.38 |
| 46 | rs11619319 | 13 | 27385599 | G | A | PDX1 | Novel | Single | Glycemic | $4.58 \times 10^{-7}$ | 8.38 |
| 47 | rs576674 | 13 | 32452302 | G | A | KL | Novel | Single | Glycemic | $1.39 \times 10^{-5}$ | 6.38 |
| 48 | rs282587 | 13 | 112399663 | G | A | ATP11A | Known | Single | Unclassified | $1.70 \times 10^{-12}$ | 13.92 |
| 49 | rs9604573 | 13 | 113571085 | T | C | GAS6 | Novel | Single | Unclassified | $9.50 \times 10^{-9}$ | 6.72 |
| 50 | rs11248914 | 16 | 233563 | T | C | ITFG3 | Novel | Single | Erythrocytic | $2.56 \times 10^{-14}$ | 10.60 |
| 51 | rs1558902 | 16 | 52361075 | A | T | FTO | Novel | Single | Unclassified | $327 \times 10^{-8}$ | 6.88 |
| 52 | rs4783565 | 16 | 67307691 | A | G | CDH3 | Novel | Single | Erythrocytic | 1. $73 \times 10^{-7}$ | 6.73 |
| 53 | rs837763 | 16 | 87381230 | T | C | CDT1 | Known | Single | Erythrocytic | $1.68 \times 10^{-28}$ | 28.89 |
| 54 | rs9914988 | 17 | 24207230 | A | G | ERAL1 | Novel | Single | Erythrocytic | $2.77 \times 10^{-11}$ | 11.34 |
| 55 | rs2073285 | 17 | 73628956 | C | T | TMC6 | Novel | Single | Unclassified | $1.27 \times 10^{-4}$ | 6.47 |
| 56 | rs1046896 | 17 | 78278822 | T | C | FN3KRP | Known | Single | Unclassified | $4.46 \times 10^{-64}$ | 71.79 |
| 57 | rs11086054 | 19 | 17107737 | A | T | MYO9B | Novel | Multiple | Unclassified | $8.16 \times 10^{-6}$ | 9.12 |
| 58 | rs17533903 | 19 | 17117523 | A | G | MYO9B | Known | Multiple | Erythrocytic | $5.27 \times 10^{-12}$ | 9.912 |
| 59 | rs4820268 | 22 | 35799537 | G | A | TMPRSS6 | Known | Single | Erythrocytic | $1.40 \times 10^{-22}$ | 20.79 |
| 60 | rs1050828 | X | 153417411 | T | C | G6PD | Novel | Single | Erythrocytic | NA* | NA |

## Different biological effects

- Glycemic associations, but not erythrocytic associations, predict future development of T2D
- ~2\% of African-Americans could be misclassified due to G6PD variant


HbA1C Gene-Level Associations


## How do these variants affect HbA1c diagnosis?



G6PD (rs1050828) Common


## How do these variants affect HbA1c diagnosis?

| Variation | Model |
| :--- | :--- |
| Rare | PIEZO1/G6PD |
| Common | Erythrocytic Variants |



## Expanding the model

- Significant associations in many sets of genes with known function on erythrocytic lifespan in mice



## Evidence for associations across many genes

- Compared to rare variants in genes involved in glycemia in mice, rare variants in erythrocytic genes are more likely to decrease HbA 1 c




## Putting this together in a polygenic score

Filtering to true associations

Filtering to erythrocytic variants
a


## Final model: 21,293 variants


**Diamonds scaled to number of reclassified individuals in the test sample

## Model is highly polygenic



## An Expanded View of Complex Traits: From Polygenic to Omnigenic

Evan A. Boyle, ${ }^{1, *}$ Yang I. Li, ${ }^{1, *}$ and Jonathan K. Pritchard ${ }^{11,2,3,{ }^{*}}$




##  あ <br> Common











## Many T2D patients carry pathogenic variants in MODY genes






## Many damaging mutations in MODY genes are incompletely penetrant



## Rare and common forms of diabetes share genes



$$
\dot{\pi} \dot{\pi} \underset{\pi}{\pi}
$$

## The ProDiGY study of T2D in youth

- Incidence of $\sim 3,700$ cases/year and increasing, particularly ages 10-19
- $15 \%$ of new diabetes cases in whites, $46-86 \%$ in minorities



## Samples

- SEARCH for Diabetes in Youth
- Longitudinal follow up to assess natural history and complication risk factors
- Active registry of youth diagnosed with diabetes at age < 20
- TODAY
- Clinical trial of ages 10-17 to compare treatment efficacy of Metformin vs Metformin+Lifestyle Intervention vs Metformin+Rosiglitazone
- BMI above 85th percentile
- Both studies are multi-ethnic

| Ancestry | Samples |
| :--- | ---: |
| African-American | $1,491(40.8 \%)$ |
| East-Asian | $62(1.7 \%)$ |
| European | $757(20.7 \%)$ |
| Hispanic | $1,306(35.9 \%)$ |
| NA | $34(0.9 \%)$ |
| Total | 3,650 |


|  | Total | Male | Female |
| :--- | ---: | ---: | ---: |
| $\mathbf{N}$ | 3,650 | $1,294(35.4 \%)$ | $2,356(64.6 \%)$ |
| Current Age | $15.2 \pm 3.0$ | $15.1 \pm 3.1$ | $15.4 \pm 2.8$ |
| Age at Onset | $13.6 \pm 2.3$ | $13.3 \pm 2.3$ | $14.1 \pm 2.2$ |

## Analysis design

- Whole exome sequencing of 3,650 youth-onset T2D cases
- Match to controls from AMP-T2D exomes
- Total analysis of 3,005 cases and 9,777 controls
- Single variant analysis (mostly for common variants)
- Gene-level analysis (for rare variants)


## ProDiGY WES <br> Youth-onset <br> T2D cases $\mathrm{N}=3,660$



Matched cases ( $\mathrm{N}=3,005$ ) and controls ( $\mathrm{N}=9,777$ ) in 7 clusters


Single variant association and Gene-level burden test

## Statistics are well-calibrated



## Four exome-wide significant associations



## Three exome-wide significant gene-level associations



- Additionally: 2.1\% of cases carry a monogenic diabetes causing variant


## Example association: HNF1A



## Substantial enrichment in diabetes-relevant gene sets

- Gene sets defined by HPO terms

HP_ABNORMAL_WAIST_TO_HIP_RATIO
HP_INSULIN_RESISTANCE



Three categories


## Enrichments are due to many genes



## Tiers of candidate genes

- Tier 1: Exome-wide significant genes (MC4R, HNF1A, ATXN2L)
- Tier 2: among top 50 and causal for monogenic diabetes or T2D (GCK, SLC30A8, ABCC8, PAM)
- Tier 3: among the top 50 and in an enriched HPO gene set (RFX6, GHRL, HESX1, SIX3)
- Tier 4: $\mathrm{p}<0.05$ and in a diabetes-relevant gene set (38 additional genes)


## Both common and rare variants are enriched in ProDiGY

(relative to adult-onset T2D cases)


## Both common and rare variants explain more heritability

 (relative to adult-onset T2D cases)

## Both common and rare variants explain more heritability

 (relative to adult-onset T2D cases)

## As a population, youth-onset T2D cases are enriched for all types of genetic risk factors

2.1\% carry monogenic variants (MODY cases)
5.0-fold more rare variants than adult-onset cases
3.4-fold more common variants than adult-onset cases
skew towards common variants in absolute terms skew towards rare variants relative to adult-onset T2D

## What about individually?



## Cases due to MODY mutations are phenotypically different





## Start with cases "explained" by rare or common variants



## No clear dividing line between cases due to rare vs. common variants

- But, a substantial amount of heterogeneity across cases



## Cases due to rare vs. common variants are phenotypically different



## Model: allelic series are pervasive across genes and pathways




- Mutations causal for monogenic diabetes mellitus - Mutations with moderate effect on insulin levels - Mutations with moderate effect on glucose levels - Mutations with moderate effect on TD2M risk - Mutations with weak effect on insulin levels - Mutations with weak effect on glucose levels - Mutations with weak effect on TD2M risk


## Model: allelic series are pervasive across genes and pathways



## Model: allelic series are pervasive across genes and pathways

Monogenic DM Neonatal DM: Lipodystrophy:


## What's next?



Biological insights
vs.

Genetic architecture



$$
\begin{aligned}
& \text { Genetic archifectues } 0
\end{aligned}
$$

$$
\begin{aligned}
& 01000010101010101101101001
\end{aligned}
$$

3:29:07.62

```
screencapture
```

Zotero
Google Chrome Helper (Renderer)
Slack Helper (Renderer)
Google Chrome Helper
圈 Activity Monitor
Slack Helper (GPU)
Google Chrome Helper (Renderer)
(9) Cisco AnyConnect Secure Mobility Clien
se_agent
com.cisco.anyconnect.macos.acsockext
ServiceDaemon
4:53:08.90

$$
0.48
$$

3:37:59.23
3:40:56.17
2:52:45.36

$$
\begin{array}{r}
45: 24.27 \\
32.79
\end{array}
$$

8:07:36.75
3:41:1
$\rightarrow$
1.1
1.0

## repmgr <br> repmgr

1.0
0.8

## JamfDaemon

httpd
mdworker_shared

## Screen Shot

sysmond
sharingd
Google Chrome Helper (Renderer)
airportd

## fseventsd

## Where will genetic associations lead us?



## Can we lead human genetics instead?



Reverse genetics

## Our organizing question

What does human genetic data tell us about a gene?
explicitly ôr implicitly




## 1. Make the data available

## ACCELERATING MEDICINES PARTNERSHIP (AMP)

Providing data and tools to promote understanding and treatment of common metabolic diseases

## 2. Help interpret the data

| Gene | GWAS | Exome |
| :---: | :---: | :---: |
| SIN3A | Minimum $\mathrm{p}=9.2 \mathrm{e}-16$ | $\mathrm{p}=0.59$ |
| FOXO1 | Minimum $\mathrm{p}=1.91 \mathrm{e}-5$ | $\mathrm{p}=0.036$ |

## 2. Help interpret the data

|  | oding variant | Compelling 95\% \| 99\% | Compelling 95\% \| $99 \%$ | Compelling $99 \% \mid 9 \%$ | Compelling 99\% \| 99\% | Compelling 99\% \| 99\% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Nearest gene | Very Strong 70\% \| 90\% | Very Strong 80\% \| 95\% | Extreme 90\% \\| 95\% | Compelling 99\% \| 99\% | Compelling 99\% \| 99\% |
|  | Coding variant | Strong 50\% \| 85\% | Very Strong 60\% \| 90\% | Very Strong <br> 75\% \| 95\% | Compelling 95\% \| 99\% | Compelling 99\% \| 99\% |
|  | GWAS locus | Moderate 15\% \| 40\% | Moderate 20\% \\| 55\% | Moderate 30\% \| 70\% | Very Strong 75\% \| 95\% | Compelling 99\% \| 99\% |
|  | No evidence | No evidence 5\% \| 20\% | Anecdotal 5\% \| 25\% | Moderate 15\% \| 45\% | Strong $50 \% \text { \| 85\% }$ | Compelling 95\% \| 99\% |
|  |  | No evidence $p \geq 0.1$ | $\begin{aligned} & \text { Weak } \\ & p<0.1 \end{aligned}$ | Nominal $p<0.05$ | $\begin{gathered} \text { Strong } \\ p<1 \times 10^{-3} \end{gathered}$ | Exome-wide $p<2.5 \times 10^{-6}$ |
|  |  | Rare Variation |  |  |  |  |

## 3. Build ever more sophisticated models



Expression pattern
Mouse phenotypes
Literature terms

## 3. Build ever more sophisticated models



## 4. Extend beyond genes to pathways

## Example pathways Diabetes component pathways



Glucagon secretion/action

## Incretin

 secretion/actionAdipose distribution



Not diabetes

## 4. Extend beyond genes to pathways


Proinsulin
номA-B





## FlannickLab

We are always seeking collaborators and motivated new members!

Contact flannick@broadinstitute.org or http://flannicklab.org



[^0]:    * Residual is after adjustment for age, gender, diabetes.

